Baxter International (BAX)
(Delayed Data from NYSE)
$35.87 USD
+0.17 (0.48%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $35.75 -0.12 (-0.33%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$35.87 USD
+0.17 (0.48%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $35.75 -0.12 (-0.33%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth D Momentum C VGM
Zacks News
Edwards Lifesciences Hits a 52-Week High on Solid Prospects
by Zacks Equity Research
Edwards Lifesciences (EW) gains from recent impressive developments.
LivaNova's (LIVN) Study to Evaluate VNS Therapy Gets CMS Nod
by Zacks Equity Research
LivaNova (LIVN) is aiming to reach out to more patients, with improved enrollment program.
Here's Why You Should Invest in Amedisys (AMED) Right Now
by Zacks Equity Research
Amedisys (AMED) is currently enjoying investors' confidence, thanks to solid prospects.
Here's Why You Should Invest in Integer Holdings (ITGR) Now
by Zacks Equity Research
Integer Holdings (ITGR) continues to benefit from portfolio management, strong foothold in the broader MedTech space and rising Non-Medical sales.
What's in Store for Aurora Cannabis (ACB) in Q4 Earnings?
by Zacks Equity Research
Aurora Cannabis (ACB) expects revenues within $100-$107 million in fiscal Q4.
Here's Why You Should Invest in Chemed (CHE) Stock Right Now
by Zacks Equity Research
Investors continue to be optimistic about Chemed's (CHE) performance.
Masimo (MASI) Introduces Pathway, Boosts Patient Monitoring
by Zacks Equity Research
Masimo's (MASI) new feature, Pathway, is likely to help clinicians simplify their workflow associated with newborn resuscitation, thereby improving patient monitoring.
Stryker's Mobius Imaging Buyout to Boost Its Spine Division
by Zacks Equity Research
Stryker (SYK) expects the buyout to remain neutral to its 2019 earnings.
Here's Why You Should Invest in Edwards Lifesciences (EW) Now
by Zacks Equity Research
Investors continue to be optimistic about Edwards Lifesciences' (EW) performance.
Here's Why You Should Hold on to Hill-Rom (HRC) Stock Now
by Zacks Equity Research
Investors' optimism continues to be high on solid prospects of Hill-Rom Holdings (HRC).
HealthEquity (HQY) Earnings & Revenues Beat Estimates in Q2
by Zacks Equity Research
HealthEquity (HQY) gains from solid segmental contributions in second-quarter fiscal 2020.
Integra LifeSciences' Organic Growth Strong on New Products
by Zacks Equity Research
Gaining traction from product unveilings and an improved sales force performance, Integra LifeSciences (IART) expects rapid organic growth in the second half of 2019.
Medtronic Names Next CEO as Omar Ishrak to Step Down in 2020
by Zacks Equity Research
This is indeed a top story as during Omar's tenure, annual revenues of Medtronic (MDT) skyrocket to double-digit growth among a slew of enormous feats that he attains.
Bruker (BRKR) Releases JPK NanoWizard 4 XP Bio-AFM System
by Zacks Equity Research
With the launch of this new system, Bruker (BRKR) establishes a performance yardstick for atomic force microscopy in the field of life science research.
Here's Why You Should Invest in Haemonetics (HAE) Right Now
by Zacks Equity Research
Haemonetics (HAE) has been enjoying investors' rising optimism, owing to solid prospects.
Here's Why You Should Hold on to DexCom (DXCM) Stock Now
by Zacks Equity Research
DexCom (DXCM) continues to benefit from growing glucose monitoring market, strategic buyouts and strong international presence. However, margin contraction remains a woe.
Here's Why You Should Hold on to Thermo Fisher (TMO) for Now
by Zacks Equity Research
Investors continue to be optimistic about Thermo Fisher's (TMO) performance.
Here's Why You Should Consider Betting on CONMED Stock Now
by Zacks Equity Research
CONMED (CNMD) continues to benefit from robust international sales, broad product portfolio and persistent focus on R&D.
Here's Why You Should Retain PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) is gaining steadily from core Diagnostics segment, prudent acquisitions and margin expansion. However, forex volatility remains a concern.
HealthEquity Acquires WageWorks, To Make Notable Investments
by Zacks Equity Research
HealthEquity (HQY) expects to complete its $80-100 million investment program within 24-36 months from now.
Here's Why You Should Invest in Hologic (HOLX) Stock Now
by Zacks Equity Research
Hologic (HOLX) is generating consistently positive results, thanks to impressive developments.
Zimmer Biomet Succeeds in Priority Areas, Suffers Pricing Woe
by Zacks Equity Research
With regard to product suite, Zimmer Biomet (ZBH) steadily wins an array of key regulatory clearances for knee, brain and spine applications under its ROSA platform over the past several months.
What's in the Cards for HealthEquity (HQY) in Q2 Earnings?
by Zacks Equity Research
Higher revenues and possible margin expansion are likely to aid HealthEquity (HQY) in Q2 earnings.
Cooper Companies (COO) Q3 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
Cooper Companies (COO) gains from solid segmental contributions in fiscal Q3.
Quest Diagnostics' New Acquisitions and Pacts Aid Growth
by Zacks Equity Research
Quest Diagnostics' (DGX) nine deals concluded in 2018 strengthen its potential to fulfill its goals set for 2019.